Mylan announced that it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Fenofibrate Tablets, the generic version of AbbVie’s Tricor.

Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. 

Fenofibrate Tablets are available in 48mg and 145mg strengths.

For more information call (800) RX-MYLAN or visit